Prognostic significance of lymphocyte patterns in multiple myeloma patients after autologous transplant

被引:4
|
作者
Stork, Martin [1 ]
Bezdekova, Renata [2 ]
Kralova, Romana [2 ]
Sandecka, Viera [1 ]
Adam, Zdenek [1 ]
Krejci, Marta [1 ]
Boichuk, Ivanna [1 ]
Knechtova, Zdenka [1 ]
Brozova, Lucie [3 ]
Sevcikova, Sabina [4 ]
Rihova, Lucie [2 ]
Pour, Ludek [1 ]
机构
[1] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic
[2] Univ Hosp Brno, Dept Clin Hematol, Brno, Czech Republic
[3] Inst Biostat & Anal Ltd, Brno, Czech Republic
[4] Masaryk Univ, Fac Med, Dept Pathophysiol, Babak Myeloma Grp, Brno, Czech Republic
关键词
multiple myeloma; minimal residual disease; lymphocyte; flow cytometry; MINIMAL RESIDUAL DISEASE; PERIPHERAL-BLOOD; BONE-MARROW; CELLS; SURVIVAL; PROGRESSION; SUBSETS; THERAPY; IMPACT; NKT;
D O I
10.4149/neo_2021_200814N861
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite the high efficacy of current induction regimens, most multiple myeloma (MM) patients relapse over time. The link between changes in the immune system and the prognosis of the disease is still not entirely clear. Therefore, we analyzed whether the pattern of bone marrow (BM) lymphocytes during routine BM examination after autologous stem cell transplant (ASCT) is related to disease prognosis or MRD negative complete remission. From 2009 to 2018, 98 MM patients underwent routine BM testing after the first ASCT. Using multi-parametric flow cytometry, twelve BM lymphocyte subtypes were analyzed. In 60% of patients who achieved a complete response (CR), MRD by flow cytometric analysis (sensitivity threshold 10-6) was evaluated. We found an association of relative proportion of BM lymphocyte subtypes with treatment response, progression-free survival (PFS), overall survival (OS), and minimal residual disease (MRD) negativity. Higher relative proportion of memory B cells was associated with inferior median PFS [HR 1.089 (95% CI: 1.023-1.160), p=0.0081 and median OS [HR 1.170 (95% CI: 1.074-1.274), p<0.001]. In non-responding patients (minimal response and worse), higher proportion of memory B cells was found when compared to patients achieving CR [3.8% (range 0.5-35.0) vs. 1.0% (range 0.1-12.5); p=0.0011. No significant association of BM lymphocyte subtypes proportion with MRD negative CR was found. Our results show that changes in BM lymphocyte subsets including memory B cells may have prognostic value in MM patients after ASCT.
引用
收藏
页码:519 / 527
页数:9
相关论文
共 50 条
  • [21] Prognostic Significance of the FISH Panel for Patients with Multiple Myeloma
    Rothman, Rachel
    Voskoboinik, Nadia
    Herishanu, Yair
    Orr-Urtreger, Avi
    Naparstek, Elizabeth
    Trestman, Svetlana
    BLOOD, 2012, 120 (21)
  • [22] Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma
    Bila, Jelena
    Sretenovic, Aleksandra
    Jelicic, Jelena
    Tosic, Natasa
    Glumac, Irena
    Fekete, Marija Dencic
    Antic, Darko
    Balint, Milena Todorovic
    Markovic, Olivera
    Milojevic, Zoran
    Radojkovic, Milica
    Trajkovic, Goran
    Puric, Mila
    Pavlovic, Sonja
    Mihaljevic, Biljana
    Clinical Lymphoma Myeloma & Leukemia, 2016, 16 (11): : 610 - 615
  • [23] Prognostic Significance of Absolute Lymphocyte Count/Absolute Monocyte Count Ratio at Diagnosis in Patients with Multiple Myeloma
    Shin, Su-Jin
    Roh, Jin
    Kim, Misung
    Jung, Min Jung
    Koh, Young Wha
    Park, Chan-Sik
    Yoon, Dok Hyun
    Suh, Cheolwon
    Park, Chan-Jeong
    Chi, Hyun Sook
    Huh, Jooryung
    KOREAN JOURNAL OF PATHOLOGY, 2013, 47 (06) : 526 - 533
  • [24] Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
    de Tute, Ruth M.
    Pawlyn, Charlotte
    Cairns, David A.
    Davies, Faith E.
    Menzies, Tom
    Rawstron, Andy
    Jones, John R.
    Hockaday, Anna
    Henderson, Rowena
    Cook, Gordon
    Drayson, Mark T.
    Jenner, Matthew W.
    Kaiser, Martin F.
    Gregory, Walter M.
    Morgan, Gareth J.
    Jackson, Graham H.
    Owen, Roger G.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) : 2889 - +
  • [25] Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
    Zhou, Huixing
    Jian, Yuan
    Du, Juan
    Liu, Junru
    Zhang, Zhiyao
    Yang, Guangzhong
    Wang, Guorong
    Tian, Ying
    Li, Yanchen
    Wu, Yin
    Chen, Wenming
    Fu, Weijun
    Li, Juan
    Gao, Wen
    CANCER MEDICINE, 2023, 12 (08): : 9085 - 9096
  • [26] Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant
    Poi, Ming J.
    Li, Junan
    Sborov, Douglas W.
    VanGundy, Zachary
    Cho, Yu Kyoung
    Lamprecht, Misty
    Pichiorri, Flavia
    Phelps, Mitch A.
    Hofmeister, Craig C.
    MOLECULAR CARCINOGENESIS, 2017, 56 (07) : 1722 - 1732
  • [27] Complete response after autologous stem cell transplant in multiple myeloma
    Kumar, Lalit
    Iqbal, Nida
    Mookerjee, Anjali
    Verma, Rakesh Kumar
    Sharma, Om D.
    Batra, Atul
    Pramanik, Raja
    Gupta, Ritu
    CANCER MEDICINE, 2014, 3 (04): : 939 - 946
  • [28] Is it necessary to do a maintenance therapy after autologous transplant in multiple myeloma?
    Macro, Margaret
    HEMATOLOGIE, 2012, 18 (04): : 208 - 210
  • [29] Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma
    Rath, Carolyn
    Yoo, Claude
    Cheplowitz, Halle
    Lo, Mimi
    Young, Rebecca
    Guglielmo, Julie
    Saunders, Ila M.
    Banerjee, Rahul
    Young, Richard
    Kumar, Anupama
    Chung, Alfred
    Rosenberg, Aaron Seth
    Costello, Caitlin
    Fine, Jeffrey
    Wilson, Machelle
    Patel, Nimish
    Banez, Marisela Tan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (07) : 1715 - 1724
  • [30] Demographic Patterns and Outcomes of Multiple Myeloma Patients Received Autologous Stem Cell Transplant: A Nationwide Analysis
    Thalambedu, Nishanth
    Atodaria, Kuldeepsinh
    Fidler, Christian Joseph
    BLOOD, 2022, 140 : 13210 - 13211